The available data strongly suggests integrating anti IL-5/IL-5 receptor therapies into EGPA treatment strategies, to enhance patients’ outcomes and reduce the long term side effects of prolonged corticosteroid therapy. This evidence concerns the gene IL5 and eosinophilic granulomatosis with polyangiitis.